188 related articles for article (PubMed ID: 26391142)
41. CYP450 mediated inhibition potential of Swertia chirata: An herb from Indian traditional medicine.
Ahmmed SM; Mukherjee PK; Bahadur S; Harwansh RK; Kar A; Bandyopadhyay A; Al-Dhabi NA; Duraipandiyan V
J Ethnopharmacol; 2016 Feb; 178():34-9. PubMed ID: 26657265
[TBL] [Abstract][Full Text] [Related]
42. Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug.
Bauman JN; Frederick KS; Sawant A; Walsky RL; Cox LM; Obach RS; Kalgutkar AS
Drug Metab Dispos; 2008 Jun; 36(6):1016-29. PubMed ID: 18332080
[TBL] [Abstract][Full Text] [Related]
43. The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone.
Zhu L; Yang X; Zhou J; Tang L; Xia B; Hu M; Zhou F; Liu Z
Food Chem Toxicol; 2013 Jan; 51():396-403. PubMed ID: 23085095
[TBL] [Abstract][Full Text] [Related]
44. Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: the contribution of cytochrome P450 3A isoforms.
Shayeganpour A; El-Kadi AO; Brocks DR
Drug Metab Dispos; 2006 Jan; 34(1):43-50. PubMed ID: 16204463
[TBL] [Abstract][Full Text] [Related]
45. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine.
Beulz-Riché D; Grudé P; Puozzo C; Sautel F; Filaquier C; Riché C; Ratanasavanh D
Fundam Clin Pharmacol; 2005 Oct; 19(5):545-53. PubMed ID: 16176333
[TBL] [Abstract][Full Text] [Related]
46. In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2013 Oct; 37(8):476-85. PubMed ID: 23857299
[TBL] [Abstract][Full Text] [Related]
47. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A.
Voorman RL; Maio SM; Hauer MJ; Sanders PE; Payne NA; Ackland MJ
Drug Metab Dispos; 1998 Jul; 26(7):631-9. PubMed ID: 9660845
[TBL] [Abstract][Full Text] [Related]
48. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
49. Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS.
Lin QM; Pang NH; Li YH; Huang HL; Zhang XD; Hu GX; Wang ZS
Chem Biol Interact; 2019 Sep; 310():108744. PubMed ID: 31299239
[TBL] [Abstract][Full Text] [Related]
50. An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib.
Wang C; Ying L; Jin M; Zhang F; Shi D; Dai Y; Zhou Z
Cancer Chemother Pharmacol; 2021 Jan; 87(1):43-52. PubMed ID: 33170322
[TBL] [Abstract][Full Text] [Related]
51. Effects of triptolide on the pharmacokinetics of cyclophosphamide in rats: a possible role of cytochrome P3A4 inhibition.
Zhang XF; Liu J; Ye F; Ji SG; Zhang N; Cao RS; He L; Wu JC; Li XF
Chin J Integr Med; 2014 Jul; 20(7):534-9. PubMed ID: 24420925
[TBL] [Abstract][Full Text] [Related]
52. Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism.
Liu YN; Chen J; Wang J; Li Q; Hu GX; Cai JP; Lin G; Xu RA
Arch Toxicol; 2023 Aug; 97(8):2133-2142. PubMed ID: 37209178
[TBL] [Abstract][Full Text] [Related]
53. Effect of Trigonella foenum-graecum L. on Metabolic Activity of CYP2D6 and CYP3A4.
Al-Jenoobi FI; Al-Thukair AA; Alam MA; Abbas FA; Al-Mohizea AM; Alkharfy KM; Al-Suwayeh SA
Forsch Komplementmed; 2015; 22(3):180-4. PubMed ID: 26335391
[TBL] [Abstract][Full Text] [Related]
54. In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates.
Zhao K; Ding M; Cao H; Cao ZX
J Pharm Pharmacol; 2012 Oct; 64(10):1445-51. PubMed ID: 22943175
[TBL] [Abstract][Full Text] [Related]
55. Comprehensive assessment of Cucurbitacin E related hepatotoxicity and drug-drug interactions involving CYP3A and P-glycoprotein.
Lu J; Zhang Y; Sun M; Liu M; Wang X
Phytomedicine; 2017 Mar; 26():1-10. PubMed ID: 28257659
[TBL] [Abstract][Full Text] [Related]
56. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs.
Nakajima M; Nakamura S; Tokudome S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Dec; 27(12):1381-91. PubMed ID: 10570018
[TBL] [Abstract][Full Text] [Related]
57. Silybin enhances the blood concentration of brexpiprazole in rats by downregulating expression of CYP3A4 and CYP2D6.
Yu C; Pan L; Wang G; Cai Z; Zhou Y; Zheng X; Chen C; Zhang X
Pharmazie; 2020 May; 75(5):198-200. PubMed ID: 32393428
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins.
Zhang B; Zhan G; Fang Q; Wang F; Li Y; Zhang Y; Zhao L; Zhang G; Li B
Mol Med Rep; 2019 Nov; 20(5):4713-4722. PubMed ID: 31545497
[TBL] [Abstract][Full Text] [Related]
59. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.
Park JY; Shon JH; Kim KA; Jung HJ; Shim JC; Yoon YR; Cha IJ; Shin JG
J Clin Psychopharmacol; 2006 Apr; 26(2):135-42. PubMed ID: 16633141
[TBL] [Abstract][Full Text] [Related]
60. Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure.
Kiss Á; Menus Á; Tóth K; Déri M; Sirok D; Gabri E; Belic A; Csukly G; Bitter I; Monostory K
Eur Arch Psychiatry Clin Neurosci; 2020 Feb; 270(1):71-82. PubMed ID: 30604050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
